Compare
China Pharma Holdings, Inc. vs ProPhase Labs, Inc. vs Marker Therapeutics, Inc. vs Camp4 Therapeutics Corp
| Latest fiscal year | China Pharma Holdings, Inc. CPHI | ProPhase Labs, Inc. PRPH | Marker Therapeutics, Inc. MRKR | Camp4 Therapeutics Corp CAMP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $4.14M | $4.34M | $3.55M | $3.50M |
| Revenue growth (YoY) | -8.5% | -35.8% | -46.2% | +436.5% |
| Gross margin | -3.2% | 31.9% | n/a | n/a |
| Operating margin | -78.2% | -415.4% | -363.5% | n/m |
| Net margin | -76.9% | -339.3% | -343.0% | n/m |
| Net income | -$3.19M | -$14.74M | -$12.16M | -$80.40M |
| EPS (Diluted) | -$0.74 | -$1.74 | -$0.79 | -$2.65 |
| Operating cash flow | $148.3K | -$8.34M | -$12.01M | -$29.55M |
| Free cash flow | $88.9K | -$8.34M | n/a | -$29.83M |
| Cash & equivalents | $345.1K | $90.0K | $16.07M | $109.52M |
| Total assets | $31.00M | $59.87M | $19.07M | $117.81M |
| Total liabilities | $8.26M | $56.36M | $2.27M | $70.10M |
| Shareholders' equity | $22.74M | $3.51M | $16.80M | $47.70M |
| Return on year-end equity | -14.0% | -420.3% | -72.4% | -168.5% |
| Shares outstanding | 15.52M | 8.97M | 16.70M | 51.90M |
Revenue, most recent five fiscal years
| Fiscal year | China Pharma Holdings, Inc. | ProPhase Labs, Inc. | Marker Therapeutics, Inc. | Camp4 Therapeutics Corp |
|---|---|---|---|---|
| Latest | $4.14M Ended 2025-12-31 | $4.34M Ended 2025-12-31 | $3.55M Ended 2025-12-31 | $3.50M Ended 2025-12-31 |
| 1 year earlier | $4.53M Ended 2024-12-31 | $6.77M Ended 2024-12-31 | $6.59M Ended 2024-12-31 | $652.0K Ended 2024-12-31 |
| 2 years earlier | $7.01M Ended 2023-12-31 | $34.98M Ended 2023-12-31 | $3.31M Ended 2023-12-31 | $350.0K Ended 2023-12-31 |
| 3 years earlier | $8.10M Ended 2022-12-31 | $122.65M Ended 2022-12-31 | $3.51M Ended 2022-12-31 | n/a |
| 4 years earlier | $9.64M Ended 2021-12-31 | $79.04M Ended 2021-12-31 | $1.24M Ended 2021-12-31 | n/a |